JSK Venture Capital invests in early-stage companies at the intersection of health, AI and applied frontier technology, backing founders with the ambition to build globally scalable category leaders.
We combine founder experience, disciplined capital and the right network to support companies from early traction to international growth.
€ 20-40M internal capital
Healthtech, medtech, femtech, mental health, agetech and animal health. We back companies improving how care is accessed, delivered, measured and scaled through technology.
Applied AI, deep tech, robotics, quantum applications, climate technologies solving high-value real-world problems.
We are not generalists. We invest selectively in sectors where we have expertise, strong conviction and the ability to create value beyond capital. Outside our core focus, we pursue only exceptional opportunities with a clear strategic fit and a credible path to global scale.
We believe the best venture investments are built on conviction, not volume.
We invest early, stay selective and build concentrated portfolios around exceptional founders solving meaningful problems.
Our role does not end with capital.
We support companies through strategic milestones, fundraising, international expansion and access to the right network.
We work both as lead and co-investors and believe that strong syndicates create stronger companies. We believe long-term partnerships create long-term value.
Surgery saves lives, but access to it remains deeply unequal. A shortage of trained surgeons, high procedure costs, and variability in outcomes are challenges facing surgery around the world today. Andromeda Surgical is developing a next-generation autonomous robotic surgical system that is redefining the paradigm of minimally invasive surgery - from a tool in the hands of a surgeon to an intelligent platform capable of operating independently.
iSono Health is ushering in a new era of preventive women’s healthcare with its fully automated and portable 3D breast ultrasound system, ATUSA™. The project was born from the personal and professional motivation of two inspiring women who, based on their own experiences, developed a technology that enables fast, comfortable, and accurate diagnostics.
Lightly Technologies is a deeptech startup building an AI-powered forensic intelligence platform to combat the fentanyl and opioid crisis. Their Lightly Hub database traces substances to their origin and connects cases across borders in real time, turning every field test into actionable cross-agency intelligence. To bring this intelligence into the field, Lightly developed Catcher, a portable device that identifies drugs and counterfeit pharmaceuticals in under 10 minutes using patented UV-fingerprinting technology.
Founder, Managing Partner & Chief Investment Officer
Investment Director
Investment Analyst
Healthtech, medtech, femtech, mental health, agetech and animal health.
We back companies improving how care is accessed, delivered, measured and scaled through technology.
Finance, IT, operations, people, organisation and marketing specialists providing targeted expertise where it can materially support portfolio companies.
Do českého startupu Lightly Technologies, který vyvíjí zařízení na odhalování původu drog a nebezpečných látek, vstoupila investiční skupina manželů Kijonkových. Brněnská firma už technologii dokonce testuje s americkou policií.
„To je můj vzor,“ vydechla Monika Štěpánová, když v redakci Forbesu viděla velkou titulní stranu se Simonou Kijonkovou. To bylo v lednu 2026, když se mladá zakladatelka deep-techového startupu Lightly dostala do letošního výběru Forbesu 30 pod 30. Vztah mezi ní a jednou z nejúspěšnějších českých podnikatelek se mezitím výrazně posunul. Simona Kijonková totiž do Lightly nyní investuje.
Český startup VETSTOR zakladatelů Lucie Brabcové a Nikoly Šafránka obdržel v rámci aktuálního investičního kola rovný jeden milion eur. Na investici se mimo jiné podílela skupina JSK Investments manželů Simony a Jaromíra Kijonkových. Získané peníze firma, jež propojuje digitální zdravotní dokumentaci zvířat s odborným poradenstvím a nabídkou služeb a produktů pro komplexní péči o mazlíčky, hodlá využít na svůj další rozvoj a chystanou expanzi do zahraničí.
The VC Fund is a dedicated Private and Growth Equity fund within JSK Investments SICAV a.s. While the Fund benefits from shared infrastructure and operational resources, it operates with independent capital allocation, defined governance, and a separate investment mandate. There is no cross-deployment of capital between strategies.
JSK Investments SICAV a.s. is a self-managed investment fund within the meaning of Section 8 of Act No. 240/2013 Coll., on Investment Companies and Investment Funds; that is, an investment fund with legal personality that, pursuant to a license issued by the Czech National Bank, is authorized to manage its own assets and exceed the applicable limit.
In Venture Capital, we support bold founders with a global vision for a healthier planet, a stronger society, and a more sustainable economy. We invest in the roots of real change through capital, company-building experience, hands-on support, and fair partnership. Our relationships are built on transparency, courage, and a shared vision for meaningful impact.
Československá obchodní banka, a.s.
ALT investiční společnost a.s.
Dummy document